Elise Rundén-Pran

Dr. Elise Rundén-Pran

NILU-Norwegian institute for air research
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in The Lancet
Verified
Journal Article
Closed access
TET Eid
T Eid
MTMj Thomas
Mj Thomas
DSDd Spencer
Dd Spencer
Elise Rundén-PranElise Rundén-Pran
Elise Rundén-Pran
JLJck Lai
Jck Lai
NLNc de Lanerolle
Nc de Lanerolle

15 September 1998 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
Elise Rundén-PranElise Rundén-Pran
Elise Rundén-Pran
PSPer O. Seglen
Per O. Seglen
FHFinn-Mogens Haug
Finn-Mogens Haug
OOOle Petter Ottersen
Ole Petter Ottersen
TWTadeusz Wieloch
Tadeusz Wieloch
JLJon Henrik Laake
Jon Henrik Laake
The regional selectivity and mechanisms underlying the toxicity of the serine/threonine protein phosphatase inhibitor okadaic acid (OA) were investigated in hippocampal slice cultures. Image analysis of propidium iodide-labeled cultures revealed that okadaic acid caused a dose- and time-dependent injury to hippocampal neurons. Pyramidal cells in the CA3 region and granule cells in the dentate gyrus were much more sensitive to okadaic acid than the pyramidal cells in the CA1 region. Electron microscopy revealed ultrastructural changes in the pyramidal cells that were not consistent with an apoptotic process. Treatment with okadaic acid led to a rapid and sustained tyrosine phosphorylation of the mitogen-activated protein kinases ERK1 and ERK2 (p44/42mapk). The phosphorylation was markedly reduced after treatment of the cultures with the microbial alkaloid K-252a (a nonselective protein kinase inhibitor) or the MAP kinase kinase (MEK1/2) inhibitor PD98059. K-252a and PD98059 also ameliorated the okadaic acid-induced cell death. Inhibitors of protein kinase C, Ca2+/calmodulin-dependent protein kinase II, or tyrosine kinase were ineffective. These results indicate that sustained activation of the MAP kinase pathway, as seen after e.g., ischemia, may selectively harm specific subsets of neurons. The susceptibility to MAP kinase activation of the CA3 pyramidal cells and dentate granule cells may provide insight into the observed relationship between cerebral ischemia and dementia in Alzheimer’s disease.

7 June 2016 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ACAndrew Collins
Andrew Collins
ABAnnangi Balasubramanyam
Annangi Balasubramanyam
LRLaura Rubio
Laura Rubio
RMRicard Marcos
Ricard Marcos
MDMarco Dorn
Marco Dorn
Maria DusinskaMaria Dusinska
Maria Dusinska
With the growing numbers of nanomaterials (NMs), there is a great demand for rapid and reliable ways of testingNMsafety—preferably usingin vitroapproaches, to avoid the ethical dilemmas associated with animal research. Data are needed for developing intelligent testing strategies for risk assessment ofNMs, based on grouping and read‐across approaches. The adoption of high throughput screening (HTS) and high content analysis (HCA) forNMtoxicity testing allows the testing of numerous materials at different concentrations and on different types of cells, reduces the effect of inter‐experimental variation, and makes substantial savings in time and cost.HTS/HCAapproaches facilitate the classification of key biological indicators ofNM‐cell interactions. Validation ofin vitroHTStests is required, taking account of relevance toin vivoresults.HTS/HCAapproaches are needed to assess dose‐ and time‐dependent toxicity, allowing prediction ofin vivoadverse effects. SeveralHTS/HCAmethods are being validated and applied forNMtesting in theFP7projectNANoREG, including Label‐free cellular screening ofNMuptake, HCA, High throughput flow cytometry, Impedance‐based monitoring, Multiplex analysis of secreted products, and genotoxicity methods—namely High throughput comet assay, High throughputin vitromicronucleus assay, andγH2AXassay. There are several technical challenges withHTS/HCAforNMtesting, as toxicity screening needs to be coupled with characterization ofNMsin exposure medium prior to the test; possible interference ofNMswithHTS/HCAtechniques is another concern. Advantages and challenges ofHTS/HCAapproaches inNMsafety are discussed.WIREs Nanomed Nanobiotechnol2017, 9:e1413. doi: 10.1002/wnan.1413This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

1 November 2017 in Food and Chemical Toxicology
Verified
Journal Article
Open access
Maria DusinskaMaria Dusinska
Maria Dusinska
JTJana Tulinska
Jana Tulinska
NYNaouale El Yamani
Naouale El Yamani
Miroslava Lehotska MikusovaMiroslava Lehotska Mikusova
Miroslava Lehotska Mikusova
ALAurelia Liskova
Aurelia Liskova
Božena SmolkováBožena Smolková
Božena Smolková
The unique properties of nanomaterials (NMs) are beneficial in numerous industrial and medical applications. However, they could also induce unintended effects. Thus, a proper strategy for toxicity testing is essential in human hazard and risk assessment. Toxicity can be tested in vivo and in vitro; in compliance with the 3Rs, alternative strategies for in vitro testing should be further developed for NMs. Robust, standardized methods are of great importance in nanotoxicology, with comprehensive material characterization and uptake as an integral part of the testing strategy. Oxidative stress has been shown to be an underlying mechanism of possible toxicity of NMs, causing both immunotoxicity and genotoxicity. For testing NMs in vitro, a battery of tests should be performed on cells of human origin, either cell lines or primary cells, in conditions as close as possible to an in vivo situation. Novel toxicity pathways, particularly epigenetic modification, should be assessed along with conventional toxicity testing methods. However, to initiate epigenetic toxicity screens for NM exposure, there is a need to better understand their adverse effects on the epigenome, to identify robust and reproducible causal links between exposure, epigenetic changes and adverse phenotypic endpoints, and to develop improved assays to monitor epigenetic toxicity.

20 May 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
Nina JeliazkovaNina Jeliazkova
Nina Jeliazkova
Margarita D. ApostolovaMargarita D. Apostolova
Margarita D. Apostolova
CACristina Andreoli
Cristina Andreoli
FBFlavia Barone
Flavia Barone
ABAndrew Barrick
Andrew Barrick
PNPenny Nymark
Penny Nymark

1 January 2020 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
GMGeorgia Melagraki
Georgia Melagraki
Panagiotis IsigonisPanagiotis Isigonis
Panagiotis Isigonis
ATAndreas Tsoumanis
Andreas Tsoumanis
DVDimitra-Danai Varsou
Dimitra-Danai Varsou
Iseult LynchIseult Lynch
Iseult Lynch
Nanotechnology has enabled the discovery of a multitude of novel materials exhibiting unique physicochemical (PChem) properties compared to their bulk analogues. These properties have led to a rapidly increasing range of commercial applications; this, however, may come at a cost, if an association to long-term health and environmental risks is discovered or even just perceived. Many nanomaterials (NMs) have not yet had their potential adverse biological effects fully assessed, due to costs and time constraints associated with the experimental assessment, frequently involving animals. Here, the available NM libraries are analyzed for their suitability for integration with novel nanoinformatics approaches and for the development of NM specific Integrated Approaches to Testing and Assessment (IATA) for human and environmental risk assessment, all within the NanoSolveIT cloud-platform. These established and well-characterized NM libraries (e.g. NanoMILE, NanoSolutions, NANoREG, NanoFASE, caLIBRAte, NanoTEST and the Nanomaterial Registry (>2000 NMs)) contain physicochemical characterization data as well as data for several relevant biological endpoints, assessed in part using harmonized Organisation for Economic Co-operation and Development (OECD) methods and test guidelines. Integration of such extensive NM information sources with the latest nanoinformatics methods will allow NanoSolveIT to model the relationships between NM structure (morphology), properties and their adverse effects and to predict the effects of other NMs for which less data is available. The project specifically addresses the needs of regulatory agencies and industry to effectively and rapidly evaluate the exposure, NM hazard and risk from nanomaterials and nano-enabled products, enabling implementation of computational 'safe-by-design' approaches to facilitate NM commercialization.